Key facts
- Notable investors include DPH Capital, Rizhao City Financial Investment Group.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Heyoute Gene
- ·The full record, as it builds
Funding rounds
No funding rounds for Heyoute Gene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Heyoute Gene
Developer of molecular diagnostic technologies intended for clinical, outpatient, and individual health-screening applications. The company's platform utilizes circular RNA biomarkers detected through fluorescence quantitative PCR and molecular hybridization techniques, enabling clients to access objective, non-invasive diagnostic solutions for conditions such as major depressive disorder, thereby supporting early detection and personalized treatment strategies.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2023
- Employees
- 50
- Website
- healedgene.com/
- Ownership
- Privately Held (backing)
Heyoute Gene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Heyoute Gene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Heyoute Gene in its N-PORT filings yet. We sweep new filings monthly.